Triple-negative breast cancer trials in Brazil
8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Where
- Barretos, Natal, Porto Alegre, Recife, São Jose Do Rio Preto, São Paulo
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00 - Phase 3Taking peopleA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Where
- Barretos, Blumenau, Fortaleza, Goiânia, Natal, Passo Fundo, Porto Alegre, Rio de Janeiro, São José do Rio Preto
- Age
- 18 years and over
- People
- 2,400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00 - Phase 3Taking peopleSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Where
- Fortaleza, Lages, Porto Alegre, Santa Cruz do Sul, São Paulo, Taubaté, Teresina, Vitória
- Age
- 18 years and over
- People
- 1,530 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00 - Phase 3Taking peopleStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Where
- Brasília, Curitiba, Ijuí, Itajaí, Natal, Porto Alegre, Recife, Rio de Janiero, Salvador, São Paulo, Teresina
- Age
- 18 years and over
- People
- 1,514 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00 - Phase 3Taking peopleROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Where
- Brasília, Curitiba, Goiânia, Pelotas, Porto Alegre, São Paulo, Vitória
- Age
- 18 years and over
- People
- 558 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00 - Phase 3Taking peopleA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Where
- Barretos, Curitiba, Florianópolis, Goiânia, Itajaí, Porto Alegre, Recife, São Paulo, Teresina
- Age
- 18 years and over
- People
- 625 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06103864 - Phase 2/3Taking peopleA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Where
- Barretos, Curitiba, Fortaleza, Lago Sul, Manaus, Porto Alegre, Rio de Janeiro, São José do Rio Preto, São Paulo, Vitória
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00 - Phase 2Taking peopleTIL-Driven De-escalated Chemotherapy in Stage I-II TNBC
- Where
- Brasília, Curitiba, Rio de Janeiro, Salvador, São Paulo
- Age
- 18 years and over
- People
- 40
- Run by
- D'Or Institute for Research and Education
See details and how to joinNCT07074106